Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine

Clinical trial NCT02605174 · COMPLETED

Trial details

NCT number: NCT02605174
Sponsor: Eli Lilly and Company
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Migraine With or Without Aura

Start date: 2016-05-01
Primary completion: 2017-06-30
Enrollment: 3005

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.